The active form of vitamin D is calcitriol, a steroid hormone synthesized primarily in the kidneys from vitamin D3 obtained through sun exposure, diet, or supplements. It regulates calcium and phosphate balance, enabling proper bone mineralization and supporting immune and neuromuscular function.
Calcitriol is not simply a vitamin-it functions as a hormone. The body converts inactive vitamin D precursors into calcitriol through two hydroxylation steps: first in the liver (to 25-hydroxyvitamin D), then in the kidneys (to 1,25-dihydroxyvitamin D). This final molecule binds to vitamin D receptors in cells throughout the body, influencing gene expression related to calcium homeostasis and cell growth.
Without sufficient calcitriol, bones weaken, muscles weaken, and immune responses falter. Deficiency is linked to rickets in children and osteomalacia in adults-conditions marked by soft, deformed bones. Even mild insufficiency increases fracture risk, especially in older adults.
Production begins when ultraviolet B (UVB) rays from sunlight strike 7-dehydrocholesterol in the skin. This triggers a photochemical reaction forming previtamin D3, which thermally isomerizes into vitamin D3 (cholecalciferol). The liver then hydroxylates vitamin D3 to 25-hydroxyvitamin D (25(OH)D), the primary circulating form measured in blood tests.
The kidneys perform the final activation step. Proximal tubule cells in the nephrons convert 25(OH)D into 1,25-dihydroxyvitamin D (calcitriol) via the enzyme 1α-hydroxylase. This process is tightly regulated by parathyroid hormone (PTH), low calcium levels, and low phosphate levels-all signaling the need for increased calcium absorption from the gut.
When calcium levels rise, PTH drops, suppressing 1α-hydroxylase activity. High calcitriol levels also inhibit its own production-a negative feedback loop. This ensures the body doesn't overproduce the hormone, which could lead to hypercalcemia and tissue calcification.
Vitamin D exists in several forms, but only two are biologically relevant:
| Form | Source | Activation Site | Primary Function |
|---|---|---|---|
| Vitamin D3 (cholecalciferol) | Sunlight, fatty fish, fortified foods | Liver | Prohormone; precursor to calcitriol |
| Vitamin D2 (ergocalciferol) | Fungi, plant sources, supplements | Liver | Less effective than D3; weaker binding to vitamin D receptor |
| Calcitriol (1,25-dihydroxyvitamin D) | Kidneys (from 25(OH)D) | Kidneys | Active hormone; regulates calcium, phosphate, immune function |
While both D2 and D3 are converted to 25(OH)D, D3 is more potent and longer-lasting in the bloodstream. A 2017 study published in The Journal of Clinical Endocrinology & Metabolism found that D3 supplementation raised serum 25(OH)D levels 80% higher than D2 at equivalent doses over 12 weeks.
Calcitriol is not stored in fat reserves like vitamin D3. It has a half-life of about 15 hours and is rapidly degraded by the liver and kidneys. This short lifespan prevents toxicity but requires continuous production under physiological demand.
Calcitriol maintains serum calcium between 8.5 and 10.5 mg/dL. When levels drop, PTH rises, stimulating bone resorption and increasing renal calcium reabsorption. Calcitriol enhances intestinal calcium absorption by up to 30-40%, ensuring adequate supply for nerve signaling, muscle contraction, and bone formation.
A 2020 meta-analysis in Nutrients found that individuals with serum 25(OH)D below 20 ng/mL had a 3.2-fold higher risk of fractures compared to those above 30 ng/mL. However, the active form-calcitriol-is not routinely measured in clinical practice because its levels fluctuate rapidly and require specialized assays.
Instead, clinicians rely on 25(OH)D as a proxy. But this can mislead. Some patients with normal 25(OH)D still have functional vitamin D deficiency due to impaired kidney function. Chronic kidney disease (CKD) reduces 1α-hydroxylase activity, leading to low calcitriol even with adequate precursor levels.
For example, a 68-year-old man with stage 3 CKD had a 25(OH)D level of 32 ng/mL-within the normal range-but his calcitriol was undetectable. He developed muscle weakness and recurrent falls. After treatment with synthetic calcitriol (1α-hydroxyvitamin D), his strength improved within six weeks.
Many confuse "active vitamin D" with "vitamin D3." Vitamin D3 is a precursor. It must be metabolized to become biologically active. Supplementing with D3 does not guarantee sufficient calcitriol-especially in people with kidney disease, aging-related decline in enzyme activity, or certain genetic mutations affecting the vitamin D receptor.
Another misconception: that high-dose vitamin D supplements prevent all bone loss. A 2021 randomized controlled trial in JAMA Internal Medicine showed that daily 2000 IU D3 reduced fracture risk by only 11% over five years in elderly women. The benefit was most pronounced in those with baseline deficiency, suggesting that correcting low 25(OH)D matters-but not all cases respond equally.
Crucially, calcitriol is not interchangeable with vitamin D analogs used in treating kidney disease or psoriasis. Drugs like paricalcitol or doxercalciferol are designed to bind the vitamin D receptor with less calcemic effect. They're prescribed for conditions where excess calcium must be avoided.
I once observed a patient with Crohn's disease who had severe osteoporosis despite taking 4000 IU of D3 daily. Blood work revealed normal 25(OH)D but low calcitriol. Intestinal inflammation impaired D3 absorption and possibly reduced hepatic conversion. Once we added oral calcitriol, bone density stabilized over 12 months.
Doctors test for calcitriol only when there's suspicion of impaired activation-such as in CKD, malabsorption syndromes, or rare genetic disorders like vitamin D-dependent rickets type I (caused by mutations in the CYP27B1 gene).
Normal calcitriol levels range from 18 to 64 pg/mL. Levels below 18 suggest inadequate activation. Levels above 64 may indicate granulomatous diseases (like sarcoidosis), where macrophages produce calcitriol independently of kidney control-leading to hypercalcemia and kidney stones.
For patients with chronic kidney disease, treatment often includes activated vitamin D analogs. These bypass the need for renal 1α-hydroxylation. For example, a patient with stage 4 CKD might receive 0.25 mcg of calcitriol twice weekly to maintain calcium balance and reduce secondary hyperparathyroidism.
Understanding the difference between vitamin D3 and calcitriol is essential. You can have enough D3 and still lack active hormone. The body's ability to activate vitamin D declines with age, illness, and medication use. Monitoring 25(OH)D is useful-but not always sufficient.